Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 January 2007, Vol. 109, No. 2, pp. 399-404.
Prepublished online as a Blood First Edition Paper on September 26, 2006; DOI 10.1182/blood-2006-05-020735.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-05-020735v1
109/2/399    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Byrd, J. C.
Right arrow Articles by Grever, M. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Byrd, J. C.
Right arrow Articles by Grever, M. R
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted May 1, 2006
Accepted August 22, 2006

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

John C. Byrd*, Thomas S Lin, James T Dalton, Di Wu, Mitch A Phelps, Beth Fischer, Mollie Moran, Kristie A Blum, Brad Rovin, Michelle Brooker-McEldowney, Sarah Broering, Larry J Schaaf, Amy J Johnson, David M Lucas, Nyla A Heerema, Gerard Lozanski, Donn C Young, Jose-Ramon Suerez, A. Dimitrios Colevas, and Michael R Grever

Division of Hematology-Oncology, Dept. of Internal Medicine, Ohio State University, Columbus, OH
Division of Pharmaceutics, College of Pharmacy, Ohio State University, Columbus, OH
Division of Nephrology, Dept. of Medicine, Ohio State University, Columbus, OH
Dept. of Pathology, Ohio State University, Columbus, OH
Biostatistical Core, Comprehensive Cancer Center, Ohio State University, Columbus, OH
Sanofi Aventis Pharmaceuticals, Bridgewater, NJ
Cancer Therapy & Evaluation Program, National Cancer Institute, Bethesda, MD

* Corresponding author; email: john.byrd{at}osumc.edu.

Despite promising pre-clinical studies with the cyclin-dependent kinase inhibitor flavopiridol in chronic lymphocytic leukemia (CLL) and other diseases, previous clinical trials with this agent have been disappointing. The discovery of differential protein binding of flavopiridol in human and bovine serum contributed to an effective pharmacokinetic derived schedule of administration of this agent. Based upon pharmacokinetic modeling using our in vitro results and data from a previous trial, we initiated a phase I study utilizing a 30 minute loading dose followed by four hour infusion administered weekly for four of six weeks in patients with refractory CLL. Forty-two patients were enrolled on three cohorts (cohort 1: 30 mg/m2 loading dose followed by 30 mg/m2 four-hour infusion; cohort 2: 40 mg/m2 loading dose followed by 40 mg/m2 four-hour infusion; and cohort 3: level 1 dose for treatments 1-4, then a 30 mg/m2 loading dose followed by 50 mg/m2 four-hour infusion). The dose limiting toxicity using this novel schedule was hyper-acute tumor lysis syndrome. Aggressive prophylaxis and exclusion of patients with leukocyte counts greater than 200 x 109/L have made this drug safe to administer at the cohort 3 dose. Of the 42 patients treated, nineteen (45%) achieved a partial response with a median response duration that exceeds 12 months. Responses were noted in patients with genetically high risk disease, including 5 of 12 (42%) with del(17p13.1) and 13 of 18 (72%) with del(11q22.3). Flavopiridol administered using this novel schedule has significant clinical activity in refractory CLL. Patients with bulky disease and high risk genetic features have achieved durable responses thereby justifying further study of flavopiridol in CLL and other diseases.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020